AMRUTANJANNSEAmrutanjan Health Care Limited· PharmaceuticalsHighNeutral
Announced Tue, 12 Aug · 15:49 IST

Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Amrutanjan Health Care reported its unaudited results for the quarter ended June 30, 2025, with revenue from operations rising about 12.3% year-on-year to ₹9,404.57 lakhs (from ₹8,373.60 lakhs in Q1 FY25). Profit after tax jumped roughly 80% to ₹831.12 lakhs (from ₹461.56 lakhs), with EPS doubling to ₹2.87 versus ₹1.80. The operating performance was supported by margin expansion, as PBT grew to ₹1,129.27 lakhs from ₹634.88 lakhs while total expenses rose at a slower pace. The Board also appointed SPNP & Associates as Secretarial Auditor for five years (FY26–FY30) and scheduled the 88th AGM for September 23, 2025, with September 16, 2025 fixed as the record date for the final dividend and AGM voting. Statutory auditor B S R & Co. LLP issued an unmodified (clean) limited review report on the results.

Likely market impact

Strong double-digit PAT growth and improved profitability margins signal healthy operational momentum, likely to be viewed positively by investors. The final dividend record date and clean audit opinion add further comfort for shareholders.